Ophthalmology is the highest volume outpatient specialty within the NHS and the medicines used for medical retinal vascular ...
When discussing how long Eylea stays in your system, it’s important to distinguish between how long the drug remains in your eye versus your bloodstream. According to the drug’s prescribing ...
The MHRA has granted marketing authorisation for Eylea ® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...
On November 27, 2025, Celltrion announced that Health Canada approved EYDENZELT® (aflibercept-boav), a biosimilar referencing Regeneron’s EYLEA® (aflibercept), in both vial and pre-filled syringe form ...
Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
Results showed both aflibercept 8mg dosing arms were noninferior and clinically equivalent to Eylea based on the change in BCVA score at week 36. The Food and Drug Administration (FDA) has approved ...
Regeneron Pharmaceuticals received approval from the U.S. Food and Drug Administration for its eye treatment Eylea HD. The approval is for Eylea to treat macular edema following retinal vein occlusion ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, discusses the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results